Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

For the first time, researchers have shown that a nonbiological molecule called a plastic antibody can work just like a natural antibody. In animal tests, the plastic particles bind to and neutralize a toxin found in bee stings; the toxin and antibody are then cleared to the liver, the same path taken by natural antibodies. Researchers are now developing plastic antibodies for a wider range of disease targets in hopes of broadening the availability of antibody therapies, which are currently very expensive.

For more than 20 years, biochemists have attempted to mimic antibodies’ ability to zero in on their targets, as part of a strategy to make more effective and cheaper therapeutics and diagnostics. “Though antibodies are produced on an industrial scale today because they’re so important, the cost is very, very high,” says Kenneth Shea, professor of chemistry at the University of California, Irvine. That’s because antibodies are grown in animals; they’re complex molecules that can’t be made in a test tube, or even by bacteria. And antibodies, like other proteins, are very fragile. Even under refrigeration, they last just months. The question Shea and others have asked for 20 years, he says, is “would it be possible to design them from inexpensive, abiotic starting materials?” Such plastic antibodies could be made cheaply and then sit on the shelf, in theory, for years.

In 2008, Shea’s group, working with researchers from the Tokyo Institute of Technology, demonstrated for the first time that plastic antibodies made using a technique called molecular imprinting could bind to a target as strongly and specifically as natural antibodies. Molecular imprinting involves synthesizing a polymer in the presence of a target molecule. The polymer grows around the target, “imprinting” it with the target’s shape. It’s analogous to making a plaster cast of one’s hand, says Shea.

Looking to the properties of natural antibodies, Shea’s group tailored the method for making polymers that more specifically target large proteins in biological solutions. Antibodies and their targets fit together like a key in a lock, or like a hand into a plaster cast. But they are also bound to their targets by chemistry and attracted by electrical interactions. Shea’s methods involve looking to the properties of the target molecule and selecting starting materials that have an affinity for that target–in this case the protein melittin, the toxin in bee stings. At the same time, the method screens for starting materials that are not attracted to other, more common blood proteins. And the group took care to make the plastic antibody smaller than previous molecularly imprinted polymers, which were too big to be recognized by the body.

6 comments. Share your thoughts »

Credit: Kenneth Shea

Tagged: Biomedicine, diagnostics, polymers, antibodies, therapy, biomaterials

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me